Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

There is a critical upcoming catalyst for Biogen shareholders, a topline read out of data from the CLARITY-AD trial in Alzheimer's due in late September. One lesson from the Aduhelm fiasco is that data that clearly shows patients benefit from treatment is required for commercial success.

Lecanemab And Biogen's Path To Growth

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?

The future looks a bit murky for this biotech giant.

Here's What Could Make This Beaten-Down Stock a Buy

Amgen

VanEck Vectors Biotech ETF

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

How Are Biotech ETFs Reacting to Q2 Earnings Releases?

Chimera Investment

Coinbase

Disney

Gap Inc

iRobot

Penn Entertainment

The best investors know how to identify winners and fill their portfolios with equities that have the best potential for returns. And at the same time, they know which stocks to avoid.

7 F-Rated Stocks to Avoid Now

SAGE Therapeutics

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help

TOKYO and CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Eisai Co., Ltd.

EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

Seagen

BioMarin Pharmaceutical

Bristol-Myers

Medpace Holdings

Merck

Thermo Fisher Scientific

Zimmer Biomet Hlds

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

These eight health-care stocks can keep you invested in the market with less worry

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The New England Journal of Medicine (NEJM) has published positive results from the cutaneous lupus erythematosus (CLE) portion of the two-part Phase 2 LILAC study (Part B) evaluating litifilimab (known as BIIB059), an investigational drug for the treatment of lupus. Litifilimab met its primary endpoint by demonstrating superior efficacy to placebo in reducing skin disease activity.

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

Advanced Micro Devices

Amazon

CF Industries Holdings

Salesforce

Ford Motor Company

Wall Street has heated up in July following June's gloomy market behavior. But if you thought it's too late to act now or even too early to buy, there are undervalued S&P 500 stocks which smartly dictate otherwise and demand going long today.

7 Undervalued S&P 500 Stocks to Buy Before Wall Street Catches On

Alkermes

GlaxoSmithKline

Teva Pharmaceutical

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Biogen Inc. BIIB, +1.34% said Tuesdsay that its experimental treatment for a type of amyotrophic lateral sclerosis (ALS), which is often referred to as Lou Gehrig's disease, has been granted Priority Review by the Food and Drug Administration. The regulator is expected to make a decision whether to approve tofersen by Jan. 25.

FDA grants Priority Review to Biogen's ALS therapy

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational drug for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The application has been granted priority review and given a Prescription Drug User Fee Act action date of January 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application, on a yet-to-be determined date. The average life expectancy for people with ALS is three to five years from time of symptom onset. There is currently no treatment targeted for SOD1-ALS.2

FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

Illumina

BIIB vs. ILMN: Which Stock Is the Better Value Option?

BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?

Biogen Inc. (BIIB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biogen Inc. (BIIB) Upgraded to Buy: What Does It Mean for the Stock?

Biogen Inc (NASDAQ: BIIB) has announced a Q2 2002 revenue of $2.589 billion. GAAP net income was $1.058 billion or $7.24 per diluted share, and non-GAAP net income was $767 million or earnings of $5.25 per diluted share.

Biogen tops Q2 2022 earnings and revenue estimates

AbbVie

Eli Lilly

The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal Trade Commission.

2nd-Quarter Earnings Results Could Impact Drug Company Shares

Biogen delivered a Q2 beat on the top and bottom lines, but a lack of important disclosures is hurting sentiment for BIIB stock. The post Biogen (BIIB) Stock Dips Following Q2 Earnings Report appeared first on InvestorPlace.

Biogen (BIIB) Stock Dips Following Q2 Earnings Report

Biogen Inc. (NASDAQ:BIIB ) Q2 2022 Results Earnings Conference Call July 20, 2022 8:00 AM ET Company Participants Michael Hencke - Head of IR Michel Vounatsos - CEO Priya Singhal - Interim Head, Research and Development Michael McDonnell - CFO Conference Call Participants Brian Abrahams - RBC Capital Markets Matthew Harrison - Morgan Stanley Colin Bristow - UBS Michael Yee - Jefferies Umer Raffat - Evercore ISI Marc Goodman - SVB Securities Salveen Richter - Goldman Sachs Robyn Karnauskas - Truist Securities Cory Kasimov - JPMorgan Jay Olson - Oppenheimer Philip Nadeau - Cowen and Company Geoff Meacham - Bank of America Evan Seigerman - BMO Capital Markets Operator Good morning. My name is Katie, and I will be your conference operator today.

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2022 Results - Earnings Call Transcript

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

Biogen Inc (NASDAQ: BIIB ) earlier lifted its full-year profit forecast after reporting blowout second-quarter profits of $5.25 per share on revenue of $2.59 billion, both of which came in above Wall Street's expectations, as sales of multiple sclerosis (MS) drug Tecfidera topped estimates.

Biogen Stock Moves Lower Despite Beat-and-Raise

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates

The company said earnings are expected to be between $15.25 and $16.75 per share for this year, more than prior expectation of $14.25 to $16.00.

Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.

Shares of Biogen Inc. were down 2.8% in premarket trading on Wednesday after the company missed on revenue in the second quarter of the year. Revenue for three of Biogen's top-selling therapies ⁠- muscular-atrophy therapy Spinraza and multiple-sclerosis drugs Tecfidera and Tysabri ⁠- was lower this quarter than in the same three months of last year.

Biogen's stock is down 2.8% after missing on revenue in the second quarter

Biogen stock fell early Wednesday after the biotech company reported adjusted profit of $5.25 per share on sales $2.59 billion in the second quarter. The post Biogen Stock Falls Despite Beat-And-Raise Q2 Report appeared first on Investor's Business Daily.

News for Biogen Stock (BIIB)